Estimation of the warfarin dose with clinical and pharmacogenetic data.
暂无分享,去创建一个
R. Altman | M. Wagner | T. Klein | N. Eriksson | B. Gage | S. Kimmel | M-T M Lee | N. Limdi | D. Page | D. Roden | M. Caldwell | J. Johnson | J. A. Johnson
[1] D. Sackett,et al. The number needed to treat: a clinically useful measure of treatment effect , 1995, BMJ.
[2] Posting Presentations at Medical Meetings on the Internet , 1999 .
[3] Andreas Fregin,et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 , 2004, Nature.
[4] Deborah A Nickerson,et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.
[5] M. Margaglione,et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005, Blood.
[6] Mark Crowther,et al. Systematic overview of warfarin and its drug and food interactions. , 2005, Archives of internal medicine.
[7] Peter Wood,et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.
[8] S. Hunt,et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose , 2005, The Pharmacogenomics Journal.
[9] M. Shearer,et al. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1 , 2004, Thrombosis and Haemostasis.
[10] P. Deloukas,et al. Association of warfarin dose with genes involved in its action and metabolism , 2006, Human Genetics.
[11] H. Halkin,et al. Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin , 2006, Thrombosis and Haemostasis.
[12] Ling-Zhi Wang,et al. A warfarin‐dosing model in Asians that uses single‐nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9 , 2006, Clinical pharmacology and therapeutics.
[13] M. Ritchie,et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans , 2006, Pharmacogenetics and genomics.
[14] V. Dolžan,et al. The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement , 2006, Thrombosis and Haemostasis.
[15] Julie A. Johnson,et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements , 2006, Clinical pharmacology and therapeutics.
[16] F. Kamali,et al. APOE genotype makes a small contribution to warfarin dose requirements. , 2006, Pharmacogenetics and genomics.
[17] B. Horne,et al. Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation , 2007, Circulation.
[18] Ingrid Glurich,et al. Evaluation of Genetic Factors for Warfarin Dose Prediction , 2007, Clinical Medicine & Research.
[19] D. Wysowski,et al. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. , 2007, Archives of internal medicine.
[20] C. Richards,et al. Medication Use Leading to Emergency Department Visits for Adverse Drug Events in Older Adults , 2007, Annals of Internal Medicine.
[21] Alan H B Wu,et al. Use of genetic and nongenetic factors in warfarin dosing algorithms. , 2007, Pharmacogenomics.
[22] Larisa H Cavallari,et al. Factors influencing warfarin dose requirements in African-Americans. , 2007, Pharmacogenomics.
[23] H. Halkin,et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. , 2007, Blood.
[24] Y. Kokubo,et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. , 2007, Thrombosis research.
[25] C. Thorn,et al. Warfarin Response and Vitamin K Epoxide Reductase Complex 1 in African Americans and Caucasians , 2007, Clinical pharmacology and therapeutics.
[26] Deepak Voora,et al. Genetic-based dosing in orthopedic patients beginning warfarin therapy. , 2007, Blood.
[27] E. Hylek,et al. Genetic Testing for Warfarin Dosing? Not Yet Ready for Prime Time , 2008, Pharmacotherapy.
[28] E. Nabel,et al. Pharmacogenomics--ready for prime time? , 2008, The New England journal of medicine.
[29] R. Lutter,et al. Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin. , 2008, Personalized medicine.
[30] Y. Caraco,et al. CYP2C9 Genotype‐guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study , 2008, Clinical pharmacology and therapeutics.
[31] R. Desnick,et al. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. , 2008, American journal of human genetics.
[32] C. Thorn,et al. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans , 2008, The Pharmacogenomics Journal.
[33] Y. Turpaz,et al. CYP4F2 genetic variant alters required warfarin dose. , 2008, Blood.
[34] Y. Caraco,et al. CYP 2 C 9 Genotype-guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation : A Prospective Randomized Controlled Study , 2011 .